Welcome to our dedicated page for Theriva Biologics news (Ticker: $TOVX), a resource for investors and traders seeking the latest updates and insights on Theriva Biologics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theriva Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theriva Biologics's position in the market.
Rhea-AI Summary
Theriva™ Biologics (TOVX) announced the acceptance of VIRAGE trial design for a Phase 2b clinical study at the 2024 ASCO Annual Meeting. The study involves VCN-01 in combination with chemotherapy for pancreatic ductal adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
-
Rhea-AI Summary
Theriva™ Biologics announced positive topline data from an investigator sponsored Phase 1 trial of VCN-01 in pediatric patients with refractory retinoblastoma. The trial, in collaboration with Sant Joan de Déu-Barcelona Children’s Hospital, showed safety and clinical outcomes supporting VCN-01's therapeutic potential in diverse cancer indications. Patients received two intravitreal injections of VCN-01, with positive outcomes in safety and antitumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
-
Rhea-AI Summary
Theriva™ Biologics presents preclinical data at ASGCT meeting showcasing enhanced anti-tumor effects of VCN-01 and liposomal irinotecan in pancreatic cancer therapy. The combination demonstrates synergy in treating human pancreatic tumors, supporting potential improved efficacy in chemotherapy regimens. Key findings include increased viral protein expression in cancer cell lines, significant tumor growth inhibition in mouse xenograft models, and ongoing transcriptional activity of VCN-01 post-administration. The abstract for the poster presentation is available on the ASGCT Congress portal, with the poster accessible starting May 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
Rhea-AI Summary
Theriva Biologics (TOVX) presents preclinical data at ASGCT meeting showing synergy between VCN-01 and liposomal irinotecan in treating pancreatic cancer. The data supports the potential of VCN-01 to combine with standard chemotherapies for difficult-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
-
Rhea-AI Summary
Theriva Biologics reports positive progress in VIRAGE Phase 2b clinical trial for PDAC, with no safety concerns raised. The company expects to complete enrollment by H1 2024. Financially, Theriva has $23.2 million in cash as of December 31, 2023, providing runway into Q1 2025. The company aims to achieve significant milestones in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
-
Rhea-AI Summary
Theriva™ Biologics (TOVX) to host a conference call to discuss financial results and corporate update for the full year 2023 on March 25, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Summary
Theriva™ Biologics (TOVX) to provide corporate update at BIO-Europe Spring Conference. Company focuses on cancer therapeutics. Presentation on March 18, 2024, in Barcelona, Spain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
-
Rhea-AI Summary
Theriva Biologics announced that the independent data monitoring committee recommended the continuation of enrollment into VIRAGE, a Phase 2b clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. The IDMC's assessment found no safety concerns, and VIRAGE remains on track to complete enrollment in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
-
Rhea-AI Summary
Theriva Biologics, Inc. (TOVX) will participate in a fireside chat at the B. Riley Securities Oncology Conference on January 18, 2024. The company is a clinical-stage developer of therapeutics for cancer and related diseases. The event will be held virtually at 9:30 a.m. ET, and the presentation replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
TOVX - Theriva Biologics Reports Positive Clinical Data and Financial Results, Expects to Complete Enrollment for VIRAGE Trial in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
Theriva Biologics, Inc.
NYSE:TOVX
TOVX Rankings
TOVX Stock Data
6.91M
16.82M
1.93%
6.14%
2.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
ROCKVILLE
About TOVX
synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).